Literature DB >> 12951644

Development of cell markers for the identification and expansion of islet progenitor cells.

You-Qing Zhang1, Nora Sarvetnick.   

Abstract

Diabetes mellitus results from the anatomical or functional loss of insulin-producing beta cells of the pancreas. Despite significant advances in current treatment, patients with diabetes still do not maintain optimal glucose levels and therefore face debilitating complications such as hypoglycemia, retinopathy or cardiovascular diseases later in life. Islet transplantation therefore holds great promise as an ultimate cure for diabetes. However, the shortage of availability of donor sources of islets for transplantation has largely hampered this therapy. In this respect, the use of alternative sources of islets such as the ex vivo culture and expansion and differentiation of functional endocrine cells for treating diabetes has been a major focus of diabetes research. The identity of the islet stem/progenitor cells has remained either elusive or at least equivocal because of the lack of cell markers for identification of these cells. Recent successes in studying the organogenesis of pancreas as well as in vitro islet progenitor cell identification studies have provided tremendous insight for the cell markers that are essential in the isolation and characterization of these cells prospectively both in vivo and in vitro. If we can identify the markers that will aid the isolation and purification of islet progenitor cells, or factors that determine pancreatic cell fate, we might be able to coerce them from turning into specific endocrine cells or pancreas in vitro. This article will focus on this subject and will review the latest achievements in the study of cell markers for islet progenitor cells. Copyright 2003 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12951644     DOI: 10.1002/dmrr.406

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  5 in total

Review 1.  Engineering Islets From Stem Cells: The Optimal Solution for the Treatment of Diabetes?

Authors:  Suya Du; Yanjiao Li; Zhen Geng; Qi Zhang; Leo H Buhler; Carmen Gonelle-Gispert; Yi Wang
Journal:  Front Immunol       Date:  2022-04-27       Impact factor: 8.786

2.  Combined gastrin and epidermal growth factor treatment induces islet regeneration and restores normoglycaemia in C57Bl6/J mice treated with alloxan.

Authors:  I Rooman; L Bouwens
Journal:  Diabetologia       Date:  2003-12-10       Impact factor: 10.122

3.  Pancreatic adenocarcinoma patients with localised chronic severe pancreatitis show an increased number of single beta cells, without alterations in fractional insulin area.

Authors:  M Campbell-Thompson; L R Dixon; C Wasserfall; M Monroe; J M McGuigan; D Schatz; J M Crawford; M A Atkinson
Journal:  Diabetologia       Date:  2008-11-11       Impact factor: 10.122

4.  Swertisin an Anti-Diabetic Compound Facilitate Islet Neogenesis from Pancreatic Stem/Progenitor Cells via p-38 MAP Kinase-SMAD Pathway: An In-Vitro and In-Vivo Study.

Authors:  Nidheesh Dadheech; Abhay Srivastava; Neha Paranjape; Shivika Gupta; Arpita Dave; Girish M Shah; Ramesh R Bhonde; Sarita Gupta
Journal:  PLoS One       Date:  2015-06-05       Impact factor: 3.240

5.  Is stage-specific embryonic antigen 4 a marker for human ductal stem/progenitor cells?

Authors:  Ivka Afrikanova; Ayse Kayali; Ana Lopez; Alberto Hayek
Journal:  Biores Open Access       Date:  2012-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.